Navigation Links
Cancer Drug Gleevec Could Fight Stroke
Date:6/23/2008

It might extend the effectiveness of clot-busting tPA, researchers say

MONDAY, June 23 (HealthDay News) -- A powerful weapon against cancer might also boost stroke patients' survival, new research suggests.

Gleevec, long hailed as a "wonder drug" against cancers such as chronic myelogenous leukemia (CML), will be tested to see if it can boost the effectiveness and limit the side effects of the clot-dissolving drug tissue plasminogen activator (tPA), an international team of researchers say.

One of the ways that Gleevec stops the growth of cancer cells is to block receptors of platelet-derived growth factor-CC (PDGF-CC), explained Daniel Lawrence, professor of cardiovascular medicine at the University of Michigan and a member of the research team.

Studies performed at his lab, as well as at Sweden's Karolinska Institute, have both shown that blocking those receptors improves the activity of tPA.

Doctors typically give tPA in the hours after an ischemic stroke, which occurs when a blood clot blocks a brain artery. About 80 percent of all strokes are ischemic, and tPA is given to dissolve the clots.

But there's a big downside with the drug: It also can increase the odds for brain hemorrhage.

Reporting in the June 22 online edition of the journal Nature Medicine, the researchers at Karolinska and in Michigan showed for the first time that tPA increases the risk of bleeding by acting on PDGF-CC, as well as the cellular receptor to which it binds. This activity makes blood vessels in the brain dangerously leaky.

However, in other laboratory tests and in animal studies, Gleevec prevented this leakiness by blocking PDGF-CC receptors.

"Blocking the receptor reduces formation of edema -- swelling of the brain -- and so even in the absence of tPA, the [Gleevec] treatment would be beneficial," Lawrence pointed out.

But Gleevec might also extend tPA's usefulne
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Symptoms Plus Blood Test Boost Ovarian Cancer Detection
2. Symptom screening plus a simple blood test improves early detection of ovarian cancer
3. Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis
4. Honor a Loved One at The American Cancer Societys Relay for Life
5. Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators
6. CT Screens for Lung Cancer Not a Cure-All
7. Pro Baseball Helps Keep Skin Cancer From Scoring
8. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
9. American Academy of Dermatology, Major League Baseball and Major League Baseball Players Association Play Sun Smart(TM) to Strike Out Skin Cancer
10. Lack of CHFR gene expression sets stage for breast cancer
11. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug Gleevec Could Fight Stroke
Cancer Drug Gleevec Could Fight Stroke
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 1VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 4Colorectal cancer 9090 1Genetically engineered mice yield clues to knocking out cancer 9086 1Genetically engineered mice yield clues to knocking out cancer 9086 2